Mycophenolate Mofetil Versus Cyclophosphamide For Therapy of Lupus Nephritis

Abstract

Background: The treatment of lupus nephritis has evolved significantly over the past two decades, with mycophenolate mofetil (MMF) emerging as a key therapeutic agent. The early work by (FK Yong & P D’Cruz, 2008) highlighted the safety profile of MMF compared to cyclophosphamide, noting that while both treatments resulted in similar rates of adverse events, the cyclophosphamide group experienced two deaths, including one from a cerebral hemorrhage and another from sepsis related to active systemic lupus erythematosus (SLE).  Literature Review: Subsequent cohort studies further reinforced the notion that MMF not only exhibits a lower incidence of infections but also shows comparable efficacy to other agents like azathioprine in maintaining remission . Notably, the versatility of MMF is underscored by case studies demonstrating its effectiveness across various manifestations of systemic lupus erythematosus (SLE), including minimal change disease (Hoon Hong et al., 2011). Moreover, systematic reviews and meta-analyses have confirmed MMF's efficacy in induction therapy, addressing pharmacokinetic considerations that may influence treatment outcomes (Rohit, 2015). Randomized control trials conducted in diverse populations further corroborated MMF’s safety and efficacy, suggesting it as a preferable option for induction therapy (Sedhain et al., 2018). The literature also emphasizes MMF's broader therapeutic implications, as it has been shown to positively affect non-renal manifestations of SLE, thereby expanding its clinical utility (Hong Jung et al., 2019).  Conclusion: In conclusion, the body of literature consistently supports the use of MMF over cyclophosphamide for lupus nephritis therapy, highlighting its superior safety profile and comparable efficacy. The ongoing exploration of MMF's mechanisms and broader applications in SLE management will likely influence future therapeutic strategies and clinical guidelines.